Samil Pharmaceutical Co.,Ltd's Equity Buyback announced on November 30, 2021, has expired with 125,939 shares, representing 0.99% for KRW 997.71 million.
November 28, 2022
Share
The company expired its plan on November 29, 2022.
SAMIL PHARMACEUTICAL CO., LTD is a Korea-based company mainly engaged in the manufacture of medicines. The Companyâs products portfolio consists of gastro-intestinal drugs such as antiulcerants, gastroprokinetic agents, digestive enzymes with nutrients and laxatives under the brand names of Plybutine, Gliptide and others; antipyretic, analgesic and anti-inflammatory agents under the brand name Brufen; nutritional supplements such as vitamins, minerals and immunosuppressants, and others including antigout agents, anti-parkinsonism agents and others. In addition, it is engaged in the provision of miscellaneous goods. The Company distributes its products within domestic market and to overseas markets. On November 29, 2013, it transferred its entire shares of a Korea-based company, which is engaged in the sale of medical products.
Samil Pharmaceutical Co.,Ltd's Equity Buyback announced on November 30, 2021, has expired with 125,939 shares, representing 0.99% for KRW 997.71 million.